The Motley Fool Discussion Boards
Industry Discussions / Biotechnology
|Subject: Re: GTXI||Date: 2/21/2012 12:51 PM|
|Author: SarahGen||Number: 24820 of 24912|
yeah no kidding... a 50% move just on an analyst call? about what will happen in a year? I mean, it's an aggressive call, but still.
and whoooosh. Down 33% today on actual news.
GTx Inc. (GTXI) said the U.S. Food and Drug Administration has halted its clinical trials for Capesaris, a potential advanced prostate cancer and hormonal treatment, due to an increased risk of blood clots.
The biopharmaceutical company said the FDA's clinical hold notification affects its Phase II loading-dose finding clinical trial, Phase IIb maintenance-dose finding clinical trial, and its Phase II clinical trial in men with castration-resistant prostate cancer.
GTx said it found an increased risk of venous thromboembolic events, or blood clots, in subjects treated with 1000 milligrams or more of Capesaris, and it asked the FDA to discuss changes in its clinical development program.
|Copyright 1996-2013 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us|